Neuroglee Therapeutics India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth 419.44%
- Ebitda 1689.62%
- Net Worth 676.31%
- Total Assets 335.02%
About Neuroglee Therapeutics India
Neuroglee Therapeutics India Private Limited (NTIPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 10 November 2021 (Three years and three months 13 days old ). Its registered office is in Bangalore, Karnataka, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Aniket Rajput and Manish Verma serve as directors at the Company.
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U72900KA2021FTC154123
- Company No.
154123
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
10 Nov 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Neuroglee Therapeutics India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aniket Rajput  | Director | 10-Nov-2021 | Current |
Manish Verma  | Director | 10-Nov-2021 | Current |
Financial Performance of Neuroglee Therapeutics India.
Neuroglee Therapeutics India Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 419.44% increase in profit. The company's net worth Soared by an impressive increase of 676.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neuroglee Therapeutics India?
In 2023, Neuroglee Therapeutics India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neuroglee Therapeutics India?
Neuroglee Therapeutics India has a workforce of 0 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neuroglee Therapeutics India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neuroglee Therapeutics India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.